ISRCTN - ISRCTN92479122: Strengthening primary health care teams with palliative care leaders

Plain English Summary

Background and study aims
Palliative care (PC), also known as end of life care, is the name given to terminally ill patients and their families in the last stages of life. According to the World Health Organization (WHO), patients with advanced cancer and other terminal diseases benefit from early identification and proactive PC. This study aims to evaluate the effectiveness of an program in which a PC leader is established in the primary health care center, and assess the effect of this on the early identification of patients in need of PC, the efficient use of health care services, and direct health care costs.

Who can participate?
GPs and nurses from the South Health District and the East Health District of Majorca.

What does the study involve?
Participating health care centers are randomly allocated to one of two groups. In health care centers in the first group, staff continue as normal for the duration of the study. In health care centers in the second group, a nurse or GP is appointed as a palliative care (PC) leader and attend a 42 hour training course in palliative care. The role of the leader is to train other staff members and promote PC, and to act as a consultant and liaison between the PC home-based services and other health professionals. Participants then implement PC statagies, which include use of a questionnaire to identify patients in need of PC and a tool to determine the complexity of PC needed for 16 months. Between 18-24 months after the start of the study, patients who died within 90 days have their electronic medical records accessed to look at death rate and the standard of palliative care provided.

What are the possible benefits and risks of participating?
GPs and nurses may benefit from a specific training in palliative care symptom managment, early identification of patient in need of palliative care, updated information in home-based PC services, diagnostic tools, and regular meetings for discussion of clinical cases with PC experts. Patients may benefit from an early detection and better management their care. There are no known risks to participants taking part in this study.

Where is the study run from?
The study is run from Baleares Health Services-IbSalut and takes place in 30 health care centers in Majorca (Spain)

When is the study starting and how long is it expected to run for?
January 2015 to December 2018

Who is funding the study?
Spanish Institute of Health Carlos III (Spain)

Who is the main contact?
Mr Alfonso Leiva
aleiva@ibsalut.caib.es

Trial website

Contact information

Type

Scientific

Primary contact

Mr Alfonso Leiva

ORCID ID

http://orcid.org/0000-0001-5306-8533

Contact details

Primary Care Management of Mallorca (Gerencia de Atención Primaria de Mallorca)
C/Reina Escalramunda 51
Palma
07005
Spain
+34 (0)971 175 893
aleiva@ibsalut.caib.es

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

pi14/01336

Study information

Scientific title

Effect of palliative care leaders on early identification of patients needing palliative care and resource utilization: a cluster randomized clinical trial

Acronym

Study hypothesis

The aim of this study is to evaluate whether appointing a palliative care (PC) leader or expert to health care teams who provide early identification of patients needing PC, encourages the appropriate use of health care services according to the complexity of the case and can reduce direct health costs and identify patients in need of palliative care earlier.

Ethics approval

Mallorca Ethical Committee of Clinical Research, 04/04/2016, ref: IB 3170/16

Study design

Cluster randomised controlled trial

Primary study design

Interventional

Secondary study design

Cluster randomised trial

Trial setting

GP practices

Trial type

Other

Patient information sheet

No participant information sheet available

Condition

Palliative care

Intervention

Participating health centers are randomised to one of two groups. Randomization and concealment will be centralized, through a single coordinating center, using a computer-generated block randomization in blocks of six.

Control group: Health centers receive organisation and training as usual for the duration of the study.

Intervention group: In participating health centers, palliative care leaders are appointed (nurses or doctors) and attend a 42 hour training course in palliative care based on “White Book” of PC training. The role of the leader is to train and promote PC, and to act as a consultant and liaison between the PC home-based services and professionals in the primary health care services. Leaders will encourage health professional in their Health care centers to early identificate and assess case complexity of patients. Leaders in the early identification and assessment of case complexity of patients receiving referral to PC home-based services will train primary health care doctors. Professionals will use The NECPAL CCOMS-ICO© questionnaire, which identifies patients in need of palliative measures, especially non-specific PC services, and the e IDC-PAL tool, which is used for determining the complexity of PC that is needed for patients with advanced-stage or terminal diseases. The intervention will be implemented 16 months from randomization.

Although the intervention is carried out in the care of patients, patients themselves are now followed up. Outcome measures are collected for the last 90 days or last months of a patient's life by reviewing anonymised electronic patient records.

Intervention type

Other

Phase

Drug names

Primary outcome measure

Early identification (90 days before death) rate is assessed through electronic record review from patients who died between 18 to 24 months from randomization

Secondary outcome measures

1. Case complexity is assessed through electronic record review from patients who died between 18 to 24 months from randomization
2. Number of patients who die at home is assessed by review of the death certificates from patients who died between 18 to 24 months from randomization
3. Total number of hospital admissions during the final month of life is assessed through electronic record review from patients who died between 18 to 24 months from randomization
4. Total number of emergency room admissions during the final month of life is assessed through electronic record review from patients who died between 18 to 24 months from randomization
5. Percentage of patients with any of the following “determinants of aggressive end-of-life care” during the final month of life is assessed through electronic record review from patients who died between 18 to 24 months from randomization
5.1. One or more admission to the emergency room
5.2. One or more admission to the hospital
5.3. One or more admission to the ICU
5.4. More than 14 days in the hospital
6. Cost of resources during the final month of life (including emergency department visits, outpatient office visits, primary health care visits, inpatient hospital stays, and ICU admissions) will be calculated by standard cost-per-unit prices, obtained from the Balearic official regional bulletin from patients who died between 18 to 24 months from randomization

Overall trial start date

01/01/2015

Overall trial end date

31/12/2018

Reason abandoned (if study stopped)

Eligibility

Participant inclusion criteria

1. GPs and nurses
2. Working at primary health care centers located in the South Health District and the East Health District of Majorca

Participant type

Health professional

Age group

Adult

Gender

Both

Target number of participants

30 health care centers

Participant exclusion criteria

Unwillingness to participate

Recruitment start date

01/02/2015

Recruitment end date

01/02/2016

Locations

Countries of recruitment

Spain

Trial participating centre

Baleares Health Services-IbSalut
C/Reina Esclaramunda 51 7
Palma
07005
Spain

Sponsor information

Organisation

Primary Care Management of Mallorca (Gerencia de Atención Primaria de Mallorca)

Sponsor details

C/Reina Esclaramunda n 9
Palma
07005
Spain
+34 (0)971 175 893
aleiva@ibsalut.caib.es

Sponsor type

Government

Website

Funders

Funder type

Hospital/treatment centre

Funder name

Instituto de Salud Carlos III

Alternative name(s)

Institute of Health Carlos III, Carlos III Health Institute, ISCIII

Funding Body Type

government organisation

Funding Body Subtype

Federal/National Government

Location